Cost-effectiveness analysis of psychosocial intervention for early stage schizophrenia in China: a randomized, one-year study

BMC Psychiatry

Jingping Zhao³  Xiaofeng Guo³  Jingfeng Qi³  Qinling Wei²  Jinguo Zhai¹  Zhanchou Zhang³ 

[1] Jining Medical College, Jining, China;Department of Psychiatry, 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, China;Institute of Mental Health, the Second Xiangya Hospital, Central South University, Key Laboratory of Psychiatry and Mental Health of Hunan Province, National Technology Institute of Psychiatry, No. 139 Renmin Middle Road, Changsha 410011, China

关键词: Psychosocial intervention;    Cost-effectiveness;    Schizophrenia;   

Others  :  1123448
DOI  :  10.1186/s12888-014-0212-0

 received in 2013-11-12, accepted in 2014-07-18,  发布年份 2014

【 摘 要 】

Background

A combination of psychosocial interventions and medications has been highly recommended as a successful treatment package for schizophrenia. Its cost-effectiveness has not been fully explored yet. The aim of the present analysis was to evaluate the cost-effectiveness of antipsychotics combined with psychosocial treatment and treatment as usual for patients with early-stage schizophrenia.

Method

Patients with schizophrenia (N = 1, 268) were assigned to the combination of medication and psychosocial intervention or treatment as usual for up to 12 months. Cost analysis included direct medical costs, direct nonmedical costs and indirect costs. Quality-adjusted life year (QALY) ratings were assessed with Short- Form 6D.

Results

Average monthly psychosocial intervention costs for combined treatment were higher than treatment as usual (p = 0.005), but no significant differences were found in direct costs, indirect costs, and total costs between two groups (all p-values ≥ 0.556). Combined treatment was associated with significant higher QALY ratings than treatment as usual (p = 0.039). Compared with treatment as usual, combined treatment resulted in a gain of 0.031 QALY ratings at an additional cost of US$ 56.4, yielding an incremental cost-effectiveness ratio of US$ 1819.4 per QALY gained.

Conclusions

Despite some limitations, our results supported that medication combined with psychosocial treatment was more cost-effective than treatment as usual for patients with early-stage schizophrenia.

Trial registration

clinicaltrials.gov Identifier: NCT00654576 webcite

【 授权许可】

   
2014 Zhang et al., licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J: The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005, 66:1122-1129.
• [2]Knapp M, Mangalore R, Simon J: The global costs of schizophrenia. Schizophr Bull 2004, 30:279-293.
• [3]The Global Burden of Disease: 2004 Update. WHO, Geneva; 2008.
• [4]Li JF, Lambert CE, Lambert VA: Predictors of family caregivers’ burden and quality of life when providing care for a family member with schizophrenia in the People’s Republic of China. Nurs Health Sci 2007, 9:192-198.
• [5]Yang Z, Liu ML: The economic cost of schizophrenia [in Chinese]. Chin Health Econ Mag 2003, 22:28-29.
• [6]Patterson TL, Leeuwenkamp OR: Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophr Res 2008, 100:108-119.
• [7]Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA: Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry 2005, 162:2220-2232.
• [8]Rosenbaum B, Valbak K, Harder S, Knudsen P, Køster A, Lajer M, Lindhardt A, Winther G, Petersen L, Jørgensen P, Nordentoft M, Andreasen AH: The Danish National Schizophrenia Project: prospective, comparative longitudinal treatment study of first-episode psychosis. Br J Psychiatry 2005, 186:394-399.
• [9]Almond S, Knapp M, Francois C, Toumi M, Brugha T: Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004, 184:346-351.
• [10]Edwards NC, Locklear JC, Rupnow MF, Diamond RJ: Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005, 23(Suppl 1):75-89.
• [11]Barnett PG, Scott JY, Krystal JH, Rosenheck RA: Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry 2005, 73:696-702.
• [12]Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J: Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006, 163:2080-2089.
• [13]Patel A, Knapp M, Romeo R, Reeder C, Matthiasson P, Everitt B, Wykes T: Cognitive remediation therapy in schizophrenia: cost-effectiveness analysis. Schizophr Res 2010, 120:217-224.
• [14]Phanthunane P, Vos T, Whiteford H, Bertram M: Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia. Cost Eff Resour Alloc 2011, 9:6. BioMed Central Full Text
• [15]Guo XF, Zhai JG, Liu ZN, Fang MS, Wang B, Wang C, Hu B, Sun X, Lv L, Lu Z, Ma C, He X, Guo T, Xie S, Wu R, Xue Z, Chen J, Twamley EW, Jin H, Zhao J: Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: A randomized, 1-year study. Arch Gen Psychiatry 2010, 67:895-904.
• [16]First MB, Spitzer RL, Gibbon M, Williams JBW, Benjamin LS: Structured Clinical Interview for DSM-IV Axis I Disorders–Clinician Version (SCID-CV). American Psychiatry Press, Washington, DC; 1997.
• [17]Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
• [18]Yang L, Li M, Tao LB, Zhang M, Nicholl MD, Dong P: Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China. Value Health 2009, 12(Suppl 3):66-69.
• [19]McCrone P, Patel A, Knapp M, Schene A, Koeter M, Amaddeo F, Ruggeri M, Giessler A, Puschner B, Thornicroft G: A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ 2009, 12:27-31.
• [20]Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002, 21:271-292.
• [21]McGhee SM, Brazier J, Lam CLK, Wong LC, Chau J, Cheung A, Ho A: Quality-adjusted life years: population-specific measurement of the quality component. Hong Kong Med J 2011, 17(Suppl 6):17-21.
• [22]Lam CLK, Brazier J, McGhee SM: Valuation of the SF-6D health states is feasible, acceptable, reliable, and valid in a Chinese population. Value Health 2008, 11:295-303.
• [23]Lam ETP, Lam CLK, Lo YYC, Grandek B: Psychometrics and population norm of the Chinese (HK) SF-36 Health Survey version 2. HK Pract 2008, 30:185-198.
• [24]Guy W: ECDEU Assessment Manual for Psychopharmacology. Rev ed. Dept of Health, Education, and Welfare, Rockville; 1976.
• [25]Endicott J, Spitzer RL, Fleiss JL, Cohen J: The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976, 33:766-771.
• [26]Pai S, Kapur RL: The burden on the family of a psychiatric patient: development of an interview schedule. Br J Psychiatry 1981, 138:332-335.
• [27]Hoch JS, Briggs A, Willan A: Something old, something new, something borrowed, something blue: a framework for the marriage of health economics and cost effectiveness analysis. Health Econ 2002, 11:415-430.
• [28]Chisholm D, Gureje O, Saldivia S, Villalón Calderón M, Wickremasinghe R, Mendis N, Ayuso-Mateos JL, Saxena S: Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis. Bull World Health Organ 2008, 86:542-551.
• [29]Zhai J, Guo X, Chen M, Zhao J, Su Z: An investigation of economic costs of schizophrenia in two areas of China. Int J Ment Health Syst 2013, 15:26. BioMed Central Full Text
• [30]Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, Lieberman JA: Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophr Res 2010, 116:118-125.
• [31]van den Brink M, van den Hout WB, Stiggelbout AM, van de Velde CJ, Kievit J: Cost measurement in economic evaluations of health care: whom to ask? Med Care 2004, 42:740-746.